01:02 PM EDT, 04/28/2025 (MT Newswires) -- Coherus BioSciences ( CHRS ) said Monday that data from its ongoing phase 1 trial evaluating CHS-114 therapy showed a confirmed partial response in a patient with head and neck squamous cell carcinoma, or HNSCC.

The study also showed more than 50% depletion of Treg cells in tumors and an increase in CD8+ T cells, supporting the drug's advancement in part 3 of the study evaluating CHS-114 with toripalimab in HNSCC, the company said.

There's an ongoing second-line phase 1 optimization study of CHS-114 plus toripalimab in HNSCC and gastric patients, with results expected in H1 of 2026, the company added.

Price: 1.01, Change: -0.02, Percent Change: -1.94